Glucose‐lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all‐cause mortality, cardiovascular events and cancer

Abstract

There was an association between increasing exogenous insulin dose and increased risk of all-cause mortality, MACE and cancer in people with type 2 diabetes. The limitations of observational studies mean that this should be further investigated using an interventional study design.

Antidiabetic medications use and cancer risk in type 2 diabetes

“…Our study, similarly to observations by Currie et al [10] and Li et al [24] revealed elevated risk of malignancy associated with insulin use, but only when not combined with metformin. This relationship was dose-dependent, which was also found by Holden et al [25]. Metaanalysis by Janghorbani et al demonstrated increased risk of malignancy associated with insulin use after 4 years of insulin treatment [23].…”

“…These observations can be explained by relatively short duration of these studies, frequent metformin use in combination with insulin, and, in addition, relatively low doses of insulin used in the ORIGIN trial. It should also be noted that the risk of malignancy associated with insulin use does not depend neither on the type of insulin (human or analog) [9,33,34], nor on the insulin treatment regimen (basal, basal/bolus or premixed) [25].…”

Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)

“…As a previous report suggested, reduction of the pancreatic β cell load could result in improved pancreatic β cell function by Ipra [14]. Further, it was recently reported that too much insulin injection and consequent hyperinsulinemia might be a risk of cardiovascular events and cancer [15]. Reduction of S-CPR and serum insulin concentration could be beneficial not only for pancreatic β cell protection but also for preventing cardiovascular events and cancer.…”

Type 2 diabetes therapeutic strategies: why don't we see the «ELEPHANT» in the room?

“…Нарастает количество данных, свидетельствующих о негативном влиянии инсулина на сердечно-сосудистый и онкологический риск при СД2 [18,19]. Интересно от-метить, что результаты последних исследований еще раз окончательно подтвердили влияние пиоглитазона на раз-витие рака мочевого пузыря [20,21].…”